Therapeutic drug and cardiovascular disease risk monitoring in patients with bipolar disorder

Journal of Affective Disorders

Volumn 102, Issue 1-3, 2007, Pages 145-151

  Kilbourne, Amy M ^a,b   Post, Edward P ^a   Bauer, Mark S ^c   Zeber, John E ^d,e   Copeland, Laurel A ^d,e   Good, Chester B ^f   Pincus, Harold Alan ^g  

^a VA Serious Mental Illness Treatment Research and Evaluation Center   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c BROWN UNIVERSITY   (United States)

^d Dissemination   (United States)

^e Mays Cancer Center at UT Health San Antonio   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^g Columbia University ^*  (United States)

Author keywords

Cardiovascular disease; Mood disorders bipolar; Quality of care

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; LITHIUM; MOOD STABILIZER; VALPROIC ACID;

ADULT; ARTICLE; BIPOLAR DISORDER; BLOOD CELL COUNT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DRUG BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; THYROID FUNCTION TEST;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CARBAMAZEPINE; CARDIOVASCULAR DISEASES; DRUG MONITORING; FEMALE; HUMANS; LITHIUM CARBONATE; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; QUALITY OF HEALTH CARE; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; VALPROIC ACID;

EID: 34447284312     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jad.2007.01.006     Document Type: Article

References (29)

1. Bauer M.S., and Mitchner L. What is a "mood stabilizer"? An evidence-based response. Am. J. Psychiatry 161 1 (2004) 3-18
2. Bauer M.S., Callahan A.M., Jampala C., et al. Clinical practice guidelines for bipolar disorder from the Dept. of Veterans Affairs. J. Clin. Psychiatry 60 1 (1999) 9-21
3. Bauer M., Unuzer J., Pincus H.A., and Lawson W.B. Bipolar Disord. MHSR 4 4 (2002) 225-229
4. Bocchetta A., and Loviselli A. Lithium treatment and thyroid abnormalities. Clin. Pract. Epidemol. Ment. Health 2 (2006) 23
5. Bocchetta A., Bernardi F., Pedditzi M., Loviselli A., Velluzzi F., Martino E., and del Zompo M. Thyroid abnormalities during lithium treatment. Acta Psychiatr. Scand. 83 3 (1991) 193-198
6. Clark N.c.a.w.A.D.A. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27 2 (2004) 596-601
7. Fenn H.H., Bauer M.S., Altshuler L., Evans D.R., Williford W.O., Kilbourne A.M., Beresford T.P., Kirk G., Stedman M., and Fiore L. Medical comorbidity and health-related quality of life in bipolar disorder across the adult age span. J. Affect. Disord. 86 1 (2005) 47-60
8. Folsom A.R., Chambless L.E., Ballantyne C.M., Coresh J., Heiss G., Wu K.K., Boerwinkle E., Mosley Jr. T.H., Sorlie P., Diao G., and Sharrett A.R. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch. Intern. Med. 166 13 (2006) 1368-1373
9. Goldberg J.F. Treatment guidelines: current and future management of bipolar disorder. J. Clin. Psychiatry 61 Supp 13 (2000) 12-18
10. Khot U.N., Khot M.B., Bajzer C.T., Sapp S.K., Ohman E.M., Brener S.J., Ellis S.G., Lincoff A.M., and Topol E.J. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 290 7 (2003) 898-904
11. Kilbourne A.M., and Pincus H. Improving quality of care for bipolar disorder. Curr. Opin. Psychiatry 17 (2004) 513-517
12. Kilbourne A.M. The burden of general medical conditions in patients with bipolar disorder. Curr. Psychiatry Rep. 7 6 (2005) 471-477
13. Kilbourne A.M., Bauer M.S., Han X., Haas G.L., Elder P., Good C.B., Shad M., Conigliaro J., and Pincus H. Racial differences in the treatment of veterans with bipolar disorder. Psychiatr. Serv. 56 12 (2005) 1549-1555
14. Kilbourne A.M., Bauer M.S., Pincus H., Williford W.O., Kirk G.F., and Beresford T. Clinical, psychosocial, and treatment differences in minority patients with bipolar disorder. Bipolar Disord. 7 1 (2005) 89-97
15. Kleiner J., Altshuler L., Hendrick V., and Hershman J.M. Lithium-induced subclinical hypothyroidism: review of the literature and guidelines for treatment. J. Clin. Psychiatry 60 4 (1999) 249-255
16. Marcus S.C., Olfson M., Pincus H.A., Zarin D.A., and Kupfer D.J. Therapeutic drug monitoring of mood stabilizers in Medicaid patients with bipolar disorder. Am. J. Psychiatr. 156 7 (1999) 1014-1018
17. Masand P.S., Schwartz T.L., Wang X., et al. Prescribing conventional antipsychotics in the era of novel antipsychotics: informed consent issues. Am. J. Ther. 9 6 (2002) 484-487
18. McCarthy J.F., and Blow F.C. Older patients with serious mental illness: sensitivity to distance barriers for outpatient care. Med. Care 42 11 (2004) 1073-1080
19. McCarthy J.F., Piette J.D., Fortney J.C., Valenstein M., and Blow F.C. Outpatient visit chaining among patients with serious mental illness. Med. Care 44 3 (2006) 257
20. Nakajima Y., Mizobuchi M., Nakamura M., et al. Mechanism of the drug interaction between valproic acid and carbapenem antibiotics in monkeys and rats. Drug Metab. Dispos. 32 12 (2004) 1383-1391
21. Newcomer J.W. Metabolic risk during antipsychotic treatment. Clin. Ther. 26 12 (2004) 1936-1946
22. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 Suppl 1 (2005) 1-93
23. Osby U., Brandt L., Correia N., Ekbom A., and Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch. Gen. Psychiatry 58 9 (2001) 844-850
24. Patsalos P.N. Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies. Epilepsia 46 Suppl 9 (2005) 140-148
25. Simon G.E., and Unutzer J. Health care utilization and costs among patients treated for bipolar disorder in an insured population. Psychiatr. Serv. 50 10 (1999) 1303-1308
26. Suppes T., Dennehy E.B., Hirschfeld R.M., Altshuler L.L., Bowden C.L., Calabrese J.R., Crismon M.L., Ketter T.A., Sachs G.S., and Swann A.C. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J. Clin. Psychiatry 66 7 (2005) 870-886
27. Unutzer J., Simon G., Pabiniak C., Bond K., and Katon W. The use of administrative data to assess quality of care for bipolar disorder in a large staff model HMO. Gen. Hosp. Psych. 22 1 (2000) 1-10
28. van Winkel R., De Hert M., et al. Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods. J. Clin. Psychiatry 67 10 (2006) 1493-1500
29. Weissman E.M., Zhu C.W., Schooler N.R., Goetz R.R., and Essock S.M. Lipid monitoring in patients with schizophrenia prescribed second-generation antipsychotics. J. Clin. Psychiatry 67 9 (2006) 1323-1326